TY  - GEN
AU  - Allen,Carl E
AU  - Marsh,Rebecca
AU  - Dawson,Peter
AU  - Bollard,Catherine M
AU  - Shenoy,Shalini
AU  - Roehrs,Philip
AU  - Hanna,Rabi
AU  - Burroughs,Lauri
AU  - Kean,Leslie
AU  - Talano,Julie-An
AU  - Schultz,Kirk R
AU  - Pai,Sung-Yun
AU  - Baker,K Scott
AU  - Andolina,Jeffrey R
AU  - Stenger,Elizabeth O
AU  - Connelly,James
AU  - Ramirez,Alyssa
AU  - Bryant,Christopher
AU  - Eapen,Mary
AU  - Pulsipher,Michael A
TI  - Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies
SN  - 1528-0020
PY  - 2019///0729
KW  - Adolescent
KW  - Adult
KW  - Alemtuzumab
KW  - therapeutic use
KW  - Antineoplastic Agents
KW  - Child
KW  - Child, Preschool
KW  - Female
KW  - Graft vs Host Disease
KW  - prevention & control
KW  - Hematopoietic Stem Cell Transplantation
KW  - methods
KW  - Humans
KW  - Infant
KW  - Lymphohistiocytosis, Hemophagocytic
KW  - therapy
KW  - Male
KW  - Melphalan
KW  - Survival Analysis
KW  - Transplantation Conditioning
KW  - Treatment Outcome
KW  - Vidarabine
KW  - analogs & derivatives
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
UR  - https://doi.org/10.1182/blood-2018-01-828277
ER  -